

Figure 1




antibody treatment	Mean tumor volume (mm^3) on day 43	TGI (Tumor growth inhibition)
control IgG	673.0	0%
7E6	163.8	76%
15E2	582.0	14%
18B1	423.5	37%

Figure 2A




antibody treatment	Mean tumor volume (mm3) on day 27	TGI (Tumor growth inhibition)
control IgG	1814.8	0%
7E6	770.7	58%
15E2	953.6	47%
18B1	875.5	52%

Figure 2B



antibody treatment	Mean tumor volume (mm3) on day 27	TGI (Tumor growth inhibition)
control IgG	1814.8	0%
7E6-5mg/kg	913.9	50%
7E6-10mg/kg	897.7	51%
7E6-20mg/kg	875.5	52%

Figure 2C



antibody treatment	Mean tumor volume (mm3) on day 27	TGI (Tumor growth inhibition)
control IgG	1044.0	0%
6G11	444.8	57%
7E6	561.0	46%
18B1	477.6	54%

Figure 3

antibody	% specific lysis		
	0.01ug/mL	0.10ug/mL	1.00ug/mL
isotope control	1 ± 1.6	2 ± 1.0	2 ± 0.4
7E6	7 ± 1.1	17 ± 1.4	29 ± 1.8
h7E6-WT	7 ± 0.8	18 ± 0.0	32 ± 0.6
h7E6-SVG	9 ± 1.7	26 ± 0.9	35 ± 2.3
h7E6-L	9 ± 1.1	27 ± 1.3	29 ± 2.3
h7E6-SVGL	7 ± 1.8	24 ± 1.0	23 ± 2.1
antl-EGFR	12 ± 2.4	32 ± 1.7	33 ± 0.9




Figure 4



1 50
hTrop1 (1) MA-------PPQVLAFGLLLAAATATFAAAQ ECVCENYK AVNCFVNNN
hTrop2 (1) MARGPGLAPPPLRLPLLLLLLAAVTGHTAAQ NCTCPTNK TVCSPDGPG
Consensus (1) PP L LLL AA AAQD C C KL V
51 100
hTrop1 (44) RQCQCTSVGAQNTVICSKLAAKCLVMKAEMNGSKLGRRAK-P-EGALQNN
hTrop2 (51) GRCQCRALGSGMAVDCSTLTSKCLLLKARMSAPKNARTLVRPSEHALVDN
Consensus (51) CQC ALGA V CS L AKCLLLKA M A K AR P E AL N
101 150
hTrop1 (92) DGLYDPDCDESGLFKAKQCNGTSTCWCVNTAGVRRTDK-DTEITCSERVR
hTrop2 (101) DGLYDPDCQPEGRFKAMQCNQTSVCWCVNSVGVRRTDKGDLSFRCDELVR
Consensus (101) DGLYDPDCD G FKAKQCN TS CWCVNS GVRRTDK D I C E VR
151 200
hTrop1 (141) TYWIEILKHRAREKPVDSKSLRTALQKEITTRYQLDPKFITSILYENNV
hTrop2 (151) THHIEILRHRPTAGAFNHSDLDAELRKLFREPYRLHPKFVAAVHYEQPT
Consensus (151) TH IIIDLKHK F L L K RY L PKFI AI YEN
201 250
hTrop1 (191) ITIDLVQNKSQKTQNDVDIADVAYYFEKDVKGESLFHSKKMDLTVNGEQ
hTrop2 (201) IQIELRQNRSQKAAGDVDIADAAYYFEKDIKGESLFQGRGGLDLRVRGE-
Consensus (201) I IDL QNSSQK DVDIAD AYYFEKDIKGESLF K LDL V GE
251 300
hTrop1 (240) LDLDPGQTLIYYVDEKAPEFSMQGLKAGVIAVIVVVVIAVVAGIVVLVIS
hTrop2 (250) -PLQYERTLIYYLDEIPPKFSMKRLTAGIIAVIVVVVIAVVAGMAVLVIT
Consensus (251) L TLIYYLDE P FSM L AGLIAVIVVVVIALVAGI VLVIS
301 325
hTrop1 (290) RKKMKYEKAEIKEGETMHFELNA
hTrop2 (299) NKKSKYKKVEIKEGELREPSL
Consensus (301) KKK AKY K EIKELGEL KE
Domain 1
Domain 2
Domain 3
Domain 4

Figure 5



1 50
hTrop2 (1) MARGPGLAPPPLRLPLLLLLVLAAVTGHTAAQDNCTCPTNKMTVCSPDGPG
mTrop2 (1) MARGLDLAP------LLLLLLAMATRFCTAQSNCTCPTNKMTVCDTNGPG
Consensus (51) MARG LAP LLLLLLA T AQ NCTCPTNKMTVC GPG
51 100
hTrop2 (51) GRCQCRALGSGMAVDCSTLTSKCLLLKARMSAPKNARLVRPSEHAIVDN
mTrop2 (45) GVCQCRAGSQVLVDCSTLTSKCLLLKARMSARKSGRLVMPSEHAILDN
Consensus (51) G CQCRALGS M VDCSTLTSKCLLLKARMSA K ARSLV PSEHAILDN
101 150
hTrop2 (101) DGLYDPDCDPEGRFKARQCNQTSVCWCVNSVGVRRTDKGDLSLRCDELVR
mTrop2 (95) DGLYDPDCDDKGRFKARQCNQTSVCWCVNSVGVRRTDKGDQSLRCDEVVR
Consensus (101) DGLYDPDCD GRFKARQCNQTSVCWCVNSVGVRRTDKGD SLRCDELVR
151 200
hTrop2 (151) THHILILRHRPTAGAFNHSDLDAELRRLFRERYKLHPKFVAAVHYEQPT
mTrop2 (145) THHILILRHRPTDRAFNHSDLDSELRRLFQERYKLHPSFLSAVHYEEPT
Consensus (151) THRILIDLRHRPT AFNHSDLDAELRRLF ERYKLHP FLAAVHYE PT
201 250
hTrop2 (201) IQIELRQNTSQKAAGDVDIADAAYYFERDIKGESLFQGRGGLDLRVRGEP
mTrop2 (195) IQIELRQNASQKSLRDVDIADAAYYFERDIKGESLFMGRRGLDVQVRGEP
Consensus (201) IQIELRQN SQKA DVDIADAAYYFERDIKGESLF GR GLDL VRGEP
251 300
hTrop2 (251) LQVERTLIYYLDEIPPKFSMKRLTAGLIAVIVVVVVALVAGMAVLVITNR
mTrop2 (245) LHVERTLIYYLDEKPPQFSMKRLTAGVIAVIAVVSVAVVAGVVVLVVTKR
Consensus (251) L VERTLIYYLDE PP FSMKRLTAGLIAVI VV VALVAGM VLVIT R
301 323
hTrop2 (301) RKSGKYKKVEIKELGELRKEPSL
mTrop2 (295) RKSGKYKKVEIKELGEMRSEPSL
Consensus (301) RKSGKYKKVEIKELGELR EPSL
Domain 1
Domain 2
Domain 3
Domain 4

Figure 6A



Figure 6B




Figure 7A



Figure 7B




Figure 8



BxPC3-027
Tumor Volume (mm3)
(Mean ± SEM)
800
600
400
200
0
48
62
76
90
104
118
132
146
160
Days Post Tumor Implantation
3 mg/kg NNCTG1-vcMMAD
3 mg/kg 7E6TG6Aclys-vcMMAD
3 mg/kg 7E6 LCQ03Aclys-vcMMAD

Figure 9A



Anti-Trop2 ADC h7E6SVG-TG6-vc0101 induces tumor regression in BxPC3 model
Tumor Volume (mm3) (Mean ± SEM)
1200
900
600
300
0
48
55
62
69
76
83
90
97
Days Post Tumor Implantation
3.00 mg/kg ctrl IgG-vc0101
0.75 mg/kg h7E6SVG-TG6-vc0101
1.50 mg/kg h7E6SVG-TG6-vc0101
3.00 mg/kg h7E6SVG-TG6-vc0101

Figure 9B



Anti-Trop2 ADC
h7E6SVG-N297Q/K222R-PEG6MMAD induces
tumor regression in BxPC3 model
Tumor Volume (mm3)
(Mean ± SEM)
1500
1200
900
600
300
0
48
55
62
69
76
83
90
97
Days Post Tumor Implantation
6.0 mg/kg negative control conjugate
1.5 mg/kg h7E6SVG-N297Q/K222R-PEG6MMAD
3.0 mg/kg h7E6SVG-N297Q/K222R-PEG6MMAD
6.0 mg/kg h7E6SVG-N297Q/K222R-PEG6MMAD

Figure 9C



Anti-Trop2 ADC
h7E6SVG-LCQ04/K222R-vc0101 induces
tumor regression in BxPC3 model
Tumor Volume (mm3)
(Mean ± SEM)
1400
1200
1000
800
600
400
200
0
52
59
66
73
80
87
94
101
108
115
Days Post Tumor Implantation
1.50 mg/kg neg ctrl IgG -vc0101
0.75 mg/kg h7E6SVG-LCQ04/K222R-vc0101
1.50 mg/kg h7E6SVG-LCQ04/K222R-vc0101

Figure 10



h7E6SVG-TG6-vc0101 and
h7E6SVG-LCQ03/K222R-vc0101 induce tumor
regression in colo205 xenograft model
Tumor Volume (mm3)
(Mean ± SEM)
1800
1500
1200
900
600
300
0
13
20
27
34
41
48
55
62
69
76
Days Post Tumor Implantation
6 mg/kg ctrl IgG-vc0101
6 mg/kg h7E6SVG-TG6-vc0101
6 mg/kg h7E6SVG-LCQ03/K222R-vc0101

Figure 11



h7E6SVG-TG6-vc0101 induces tumor regression in Ova196756 PDX model
Tumor Volume (mm3) (Mean ± SEM)
1000
800
600
400
200
0
155 169 183 197 211 225 239 253 267 281
Days Post Tumor Implantation
1.50 mg/kg neg ctrl IgG -vc0101
0.75 mg/kg h7E6SVG-TG6-vc0101
1.50 mg/kg h7E6SVG-TG6-vc0101

Figure 12A



h7E6SVG-TG6-vc0101 induces tumor regression in Pan0146 PDX model
Tumor Volume (mm3) (Mean ± SEM)
1500
1200
900
600
300
0
26 33 40 47 54 61 68 75 82 89 96 103 110 117
Days Post Tumor Implantation
3.00 mg/kg ctrl IgG-vc0101
0.75 mg/kg h7E6SVG-TG6-vc0101
1.50 mg/kg h7E6SVG-TG6-vc0101
3.00 mg/kg h7E6SVG-TG6-vc0101
75 mg/kg Gemcitabine (2qw) 6 doses

Figure 12B



h7E6SVG-TG6-vc0101 induces long term tumor regression in Pan0146 PDX model through continued dosing
Tumor Volume (mm3) (Mean ± SEM)
1200
900
600
300
0
35
42
49
56
63
70
77
84
Days Post Tumor Implantation
3.00 mg/kg neg ctrl IgG-vc0101
0.75 mg/kg h7E6SVG-TG6-vc0101 (qwx4)
1.50 mg/kg h7E6SVG-TG6-vc0101 (q2wx2)
3.00 mg/kg h7E6SVG-TG6-vc0101 (1x)
75 mg/kg Gemcitabine (qwx4)

Figure 13




h7E6SVG N297Q/K222R PEG6MMAD induces tumor regression in Pan144607 PDX model
Tumor Volume (mm3) (Mean ± SEM)
1500
1200
900
600
300
0
34
48
62
76
90
104
118
Days Post Tumor Implantation
6.0 mg/kg Neg ctrl IgG- N297QPEG6MMAD
1.5 mg/kg h7E6SVG-N297Q/K222R-PEG6MMAD
3.0 mg/kg h7E6SVG-N297Q/K222R-PEG6MMAD
6.0 mg/kg h7E6SVG-N297Q/K222R-PEG6MMAD

Figure 14


h7E6SVG-N297Q/K222R induces tumor regression
in Pan0135 PDX model
Tumor Volume (mm3)
(Mean ± SEM)
1200
900
600
300
0
80
94
108
122
136
150
164
178
192
Days Post Tumor Implantation
6 mg/kg neg ctrl conjugate
6 mg/kg h7E6SVG-N297Q/K222R-PEG6MMAD